Evidence map›Paper›PMID 30936548›Full record

ArticleNature medicine2019

Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation.

Andrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, Edoardo Pasolli, Federica Armanini, Moreno Zolfo, Francesco Beghini, Serena Manara, Nicolai Karcher, Chiara Pozzi and 29 more

Erratum issued 3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 634 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
634citing papers in PubMed, 6 pooled it
37.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
NCT06588166 recruitingnot on this mapstarted 2024, after this paper: background citation

A Non-invasive Gut Microbiome-based Diagnostic Tool for the Screening of Colorectal Cancer

TypeobservationalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2024 to 2027Enrolled1,006ConditionsColorectal CancerArmsGut microbiome testing
NCT06738173 recruitingnot on this mapstarted 2025, after this paper: background citation

A Gut Microbiome-based Diagnostic Tool for the Screening of Colorectal Cancer

TypeobservationalSponsorCatholic University of the Sacred HeartRan2025 to 2029Enrolled1,202ConditionsColorectal CancerArmsGut microbiome testing
3 · Its place in the literature

Who cites it

634 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,014 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention.Cancer prevention research (Philadelphia, Pa.) · 2025
    Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Review
  14. The role of adhesins ofGut microbes · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Gut Microbial Topology and Metabolic Signatures Associated With Colorectal Neoplasia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  19. Review
  20. Review

574 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 15 institutions in 7 countries.

Andrew Maltez Thomas *Department CIBIO, University of Trento, Trento, Italy.ORCID http://orcid.org/0000-0001-5789-3354
Paolo Manghi *Department CIBIO, University of Trento, Trento, Italy.
Francesco AsnicarDepartment CIBIO, University of Trento, Trento, Italy.ORCID http://orcid.org/0000-0003-3732-1468
Edoardo PasolliDepartment CIBIO, University of Trento, Trento, Italy.
Federica ArmaniniDepartment CIBIO, University of Trento, Trento, Italy.
Moreno ZolfoDepartment CIBIO, University of Trento, Trento, Italy.ORCID http://orcid.org/0000-0001-6661-4046
Francesco BeghiniDepartment CIBIO, University of Trento, Trento, Italy.ORCID http://orcid.org/0000-0002-8105-9607
Serena ManaraDepartment CIBIO, University of Trento, Trento, Italy.
Nicolai KarcherDepartment CIBIO, University of Trento, Trento, Italy.
Chiara PozziIEO, European Institute of Oncology IRCCS, Milan, Italy.
Sara GandiniIEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-1348-4548
Davide SerranoIEO, European Institute of Oncology IRCCS, Milan, Italy.
Sonia TaralloItalian Institute for Genomic Medicine, Turin, Italy.ORCID http://orcid.org/0000-0003-0887-2607
Antonio FrancavillaItalian Institute for Genomic Medicine, Turin, Italy.ORCID http://orcid.org/0000-0003-1594-2837
Gaetano GalloDepartment of Surgical and Medical Sciences, University of Catanzaro, Catanzaro, Italy.ORCID http://orcid.org/0000-0003-1066-4671
Mario TrompettoDepartment of Colorectal Surgery, Clinica S. Rita, Vercelli, Italy.
Giulio FerreroDepartment of Computer Science, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-4580-0680
Sayaka MizutaniSchool of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
Hirotsugu ShiromaSchool of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
Satoshi ShibaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0477-210X
Shinichi YachidaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Takuji YamadaSchool of Life Science and Technology, Tokyo Institute of Technology, Tokyo, Japan.
Jakob WirbelStructural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4073-3562
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4339-3492
Cornelia M UlrichHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
Hermann BrennerDivision of Preventive Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
Manimozhiyan ArumugamNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-0886-9101
Peer BorkStructural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2627-833X
Georg ZellerStructural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1429-7485
Francesca CorderoDepartment of Computer Science, University of Turin, Turin, Italy.
Emmanuel Dias-NetoMedical Genomics Laboratory, CIPE/A.C. Camargo Cancer Center, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-5670-8559
João Carlos SetubalBiochemistry Department, Chemistry Institute, University of São Paulo, São Paulo, Brazil.
Adrian TettDepartment CIBIO, University of Trento, Trento, Italy.
Barbara PardiniItalian Institute for Genomic Medicine, Turin, Italy.ORCID http://orcid.org/0000-0001-9571-4257
Maria RescignoMucosal Immunology and Microbiota Unit, Humanitas Research Hospital, Milan, Italy.
Levi WaldronGraduate School of Public Health and Health Policy, City University of New York, New York, NY, USA.ORCID http://orcid.org/0000-0003-2725-0694
Alessio NaccaratiItalian Institute for Genomic Medicine, Turin, Italy.ORCID http://orcid.org/0000-0001-5774-0905
Nicola SegataDepartment CIBIO, University of Trento, Trento, Italy. nicola.segata@unitn.it.ORCID http://orcid.org/0000-0002-1583-5794
University of Trento · ITItalian institute for Genomic Medicine · ITEuropean Institute of Oncology · ITTokyo Institute of Technology · JPUniversidade de São Paulo · BREuropean Molecular Biology Laboratory · DEGerman Cancer Research Center · DEUniversity of Turin · ITCity University of New York · USMagna Graecia University · ITMax Delbrück Center · DEOsaka International Cancer Institute · JPThe University of Tokyo · JPUniversity of Copenhagen · DKUniversity of Utah · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Cancer Genomics:Integrative and Scalable Solutions in R / BioconductorU24CA180996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T, WALDRON, LEVI · 2014 to 2023
$6.9M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Exploiting Public Metagenomic Data to Uncover Cancer-Microbiome RelationshipsR01CA230551 · NCI · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI Levi Waldron · 2020 to 2026
$3.9M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
The representative microbiome: social determinants and tools for population researchR21AI121784 · NIAID · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI DOWD, JENNIFER BEAM · 2016 to 2017
$446k
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA230551NCI NIH HHS U01 CA206110NCI NIH HHS U24 CA180996NIAID NIH HHS R21 AI121784
6 · The paper itself

Abstract

Several studies have investigated links between the gut microbiome and colorectal cancer (CRC), but questions remain about the replicability of biomarkers across cohorts and populations. We performed a meta-analysis of five publicly available datasets and two new cohorts and validated the findings on two additional cohorts, considering in total 969 fecal metagenomes. Unlike microbiome shifts associated with gastrointestinal syndromes, the gut microbiome in CRC showed reproducibly higher richness than controls (P < 0.01), partially due to expansions of species typically derived from the oral cavity. Meta-analysis of the microbiome functional potential identified gluconeogenesis and the putrefaction and fermentation pathways as being associated with CRC, whereas the stachyose and starch degradation pathways were associated with controls. Predictive microbiome signatures for CRC trained on multiple datasets showed consistently high accuracy in datasets not considered for model training and independent validation cohorts (average area under the curve, 0.84). Pooled analysis of raw metagenomes showed that the choline trimethylamine-lyase gene was overabundant in CRC (P = 0.001), identifying a relationship between microbiome choline metabolism and CRC. The combined analysis of heterogeneous CRC cohorts thus identified reproducible microbiome biomarkers and accurate disease-predictive models that can form the basis for clinical prognostic tests and hypothesis-driven mechanistic studies.

Indexed as

MetagenomicsBiomarkers, TumorCholineCohort StudiesColorectal NeoplasmsDatabases, GeneticGastrointestinal MicrobiomeHumansLyasesSpecies SpecificityBiomarkers, TumorCholineLyases

Identifiers

PMID30936548
PMCPMC9533319
OpenAlexW2932049125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.